VentriPoint Diagnostics Ltd.VPT.V

Health Care · Health Care Equipment & Services · TSX-V · Canada · ventripoint.com

VentriPoint Diagnostics Ltd. is a medical device company that develops and commercializes the Ventripoint Medical System (VMS), an AI-assisted cardiac imaging platform that generates three-dimensional models of heart chambers from standard ultrasound equipment. The company is headquartered in Toronto, Canada, and its technology is used for monitoring patients with congenital heart disease, pulmonary hypertension, and other cardiac conditions. VentriPoint received a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies category.

Key ratios

FCF / Sales

-954.7%TTM

2024 -3556.9%2023 -7731.5%2022 -6065.5%

ROA

-423.7%TTM

2024 -236.2%2023 -78.4%2022 -39.6%

ROE

-2972.6%TTM

2023 -205.4%2022 -75.6%

Revenue growth

28.6%TTM

2024 93.5%2023 -27.9%

Recent news

Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging 2026-08-12 · GlobeNewswire Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance 2026-06-15 · TheNewsWire Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential 2026-04-20 · TheNewsWire

Track VPT.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer